CoChat

Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus

Open access
Rodríguez Jiménez, Beatriz, Rodríguez de Vera Gómez, Pablo, Belmonte Lomas, Samuel, Mesa Díaz, Ángel Manuel, Caballero Mateos, Irene, Galán, Irene, Morales Portillo, Cristóbal, Martínez-Brocca, María Asunción · 2024 · Frontiers in Endocrinology

The DOI matches its Crossref record; 63 of the 70 references it cites were found in a registry or an index; 6 of the 27 sources its claims cite were checked for support.

Abstract

Background: Glucagon-like peptide-1 receptor-agonists (GLP-1ra), such as semaglutide, have emerged as promising treatments, demonstrating sustained weight reduction and metabolic benefits. This study aims to assess the impact of oral and subcutaneous semaglutide on body composition and metabolic parameters in patients with T2DM and obesity. Methods: A 24-week quasi-experimental retrospective study including adults with T2DM and obesity (BMI ≥ 30 kg/m²) who were treated with either daily-oral or weekly-subcutaneous semaglutide. Body composition was measured using bioelectrical impedance analysis, evaluating fat mass, fat-free mass, total body water, skeletal muscle mass, and whole-body phase angle. Analytical parameters included lipid profile and glycaemic control. Statistical analyses were performed using SPSS v.26. Results: Participants (n=88) experienced significant weight loss after treatment with semaglutide (9.5% in subcutaneous, 9.4% in oral, P<0.001). Weight reduction primarily resulted from fat mass reduction without substantial lean mass compromise. Visceral fat area decreased, whiles phase-angle remained stable. Improvements in lipid profiles and glycaemic control were observed, with a decrease in both HbA1c and insulin requirements. Multivariate analysis demonstrated comparable impacts of oral and subcutaneous semaglutide on body composition. Conclusion: Semaglutide, administered orally or subcutaneously, demonstrated positive effects on body composition, metabolic and glycaemic control in patients with T2DM and obesity. This real-world study highlights the potential of bioelectrical impedance analysis in assessing antidiabetic drugs' impact on body composition, providing valuable insights for future research and clinical applications.

Overview

CoChat Summary

## TL;DR

This 24-week retrospective quasi-experimental study in 88 adults with T2DM and obesity found that oral and subcutaneous semaglutide produced similar weight loss and improvements in body composition, with most weight loss coming from fat mass rather than lean mass. Glycaemic and lipid parameters also improved, and the authors report no meaningful difference between oral and subcutaneous administration in the multivariate analysis.

## Key findings

  • Among 88 participants (55 subcutaneous, 33 oral), weight decreased by 9.5% with subcutaneous semaglutide and 9.4% with oral semaglutide (P < 0.001).
  • Weight loss was driven mainly by fat loss: fat mass percentage fell by -4% in the subcutaneous group and -5.2% in the oral group, while fat-free mass percentage increased by 3.6% and 5.2%, respectively.
  • Visceral fat area decreased by -30.2 cm² with subcutaneous semaglutide and -42.3 cm² with oral semaglutide; phase angle remained stable in both groups.
  • Metabolic measures improved: total cholesterol fell by -30 mg/dl (subcutaneous) and -49.4 mg/dl (oral), HbA1c fell by -3.8% and -3%, and 92.3% of subcutaneous vs 75.8% of oral patients achieved HbA1c <7%.
  • Multivariate analysis found that fat-mass loss was associated with baseline fat mass, baseline BMI, and concomitant iSGLT2/insulin treatment, but not with semaglutide route of administration.

## Methods

  • Design: 24-week quasi-experimental retrospective real-world study, conducted in the Endocrinology and Nutrition Department of Virgen Macarena University Hospital (Seville) during 2020–2022.
  • Sample: Adults ≥18 years with T2DM, HbA1c ≥7%, and BMI ≥30 kg/m² treated with oral or subcutaneous semaglutide; 88 patients were included after exclusions.
  • Analysis: Body composition was assessed with multi-frequency bioelectrical impedance analysis (InBody 770) at baseline and week 24; laboratory outcomes included glycaemic control and lipid profile. Statistical analysis used SPSS v.26, with group comparisons and multiple linear regression for predictors of fat-mass loss.

## Limitations

  • The paper states there was no control group, the follow-up was limited to 24 weeks, the sample size was narrow, and the study’s retrospective nature is a weakness.
  • The authors also state they could not compare the treatment groups directly because of baseline differences.
  • They note that bioelectrical impedance analysis is not the gold standard for body composition measurement.
  • Evident from the text: because patients with intolerance/adverse effects were excluded, the results may underrepresent less-tolerant semaglutide users.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fendo.2024.1386542

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study design–dose range administration. In order to obtain comparable data, only patients who followed a monthly dose escalation as represented by d and h, were selected. In brackets are the number of patients who followed each treatment scheme. SS, subcutaneous semaglutide; OS, oral semaglutide; mg, milligrams; M, months.
Figure 1 Study design–dose range administration. In order to obtain comparable data, only patients who followed a monthly dose escalation as represented by d and h, were selected. In brackets are the number of patients who followed each treatment scheme. SS, subcutaneous semaglutide; OS, oral semaglutide; mg, milligrams; M, months.CC BY · PubMed Central
Figure 2 Changes in the composition parameters from baseline to end of follow-up.
Figure 2 Changes in the composition parameters from baseline to end of follow-up.CC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 1 Not valid · 16 Not checked · 43 Own results and interpretations

19 more claims

Create a free account to see all 65 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 25
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 63 references

Research works printed but not linked: 1

  1. Carreira, 2022, Aplicaciones del ángulo de fase de la bioimpedancia en la nutrición clínica, Nutr Clín Med, 33, 10.7400/NCM.2022.16.1.5107 · doi:10.7400/ncm.2022.16.1.5107

Cited by

See all 39

Metadata

Authors
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A.
Affiliations
Hospital Universitario Virgen Macarena (ES)
Venue
Frontiers in Endocrinology
Published
2024-06-04
Volume
15
Pages
1386542-1386542
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4399330051
Cited by
39
References
70
Citations by year
2026: 19 · 2025: 18 · 2024: 2
FWCI
12.76
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, body composition, obesity, type 2 diabetes, GLP-1 receptor agonists, oral semaglutide, fat mass reduction, visceral fat, fat-free mass, phase angle, lipid profile, glycemic control, HbA1c, insulin requirement, weight loss
MeSH terms
Semaglutide, Adult, Aged, Blood Glucose, Body Composition, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Retrospective Studies, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. https://app.cochat.ai/papers/10.3389/fendo.2024.1386542
The paper
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A. (2024). Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2024.1386542

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.